Kantar Health Oncology – broad and unparalleled global reach coupled with deep local knowledge

Non-Small Cell Lung Cancer – a global view on standards of care and patient outcomes

We have robust and clinically rich oncology data in all major regions of the world. We've highlighted a portion of non-small cell lung cancer (NSCLC) data in Japan, Germany, China, Brazil and the United States from two of our best-in-class databases: National Health and Wellness Survey (NHWS) and CancerMPact®. Click on the tabs below to reveal data and our synopses.


  • Demographics and Data
    • Incidence
    • Incidence Rank
    • 5-Year Prevalence
  • Health and Lifestyle
    • Comorbidities, COPD
    • Comorbidities, Emphysema
    • Comorbidities, Bronchitis
    • Ever Smoked Cigarettes
    • Currently smoke cigarettes
  • Patient Background
    • Mean Age
    • Employed Full-Time
    • Sex (Male)
    • Sex (Female)
    • Insurance Type
  • Early-Stage Treatment
    • Stages I/II
    • Stage IIIA
  • Late-Stage Treatment
    • First-Line, Squamous
    • Second-Line, Squamous
    • First-Line, Non-Squamous WT
    • Second-Line, Non-Squamous WT
    • First-Line, EGFR-Mutant
    • Second-Line, EGFR-Mutant
    • First-Line, ALK-Mutant
    • Second-Line, ALK-Mutant
  • Biomarker Histology
    • % of Patients Tested for EGFR Mutation
    • % of Patients Tested for ALK Mutation
    • % of Patients Whose Tumors Harbor an EGFR Mutation
    • % of Patients Whose Tumors Harbor an ALK Mutation

To learn more about our oncology-related products and services, contact us. Download PDF >